Regulus Therapeutics (RGLS) is in Overbought Territory: What’s Next? – Tale of the Tape

What is RSI?

RSI stands for ‘Relative Strength Index’ and it is a popular indicator used by technically focused investors. It compares the average of gains in days that closed up to the average of losses in days that closed down; readings above 70 suggest an asset is overbought, while an RSI below 30 suggests undervalued conditions are present.

Other Factors

Yet RGLS’ high RSI value isn’t the only reason for investors to be concerned, as there has been some decidedly negative earnings estimate revisions in Regulus Therapeutics’ stock as of late. This is especially true when investors dive into some of these revisions in order to get a better picture of RGLS’ prospects for the near term.

Over the past two months, investors have witnessed 1 earnings estimate revision lower compared to none higher for the current year. The consensus estimate for RGLS has also been on a downward trend over the same time period too, as the estimate has fallen from -$1.03/share two months ago to just -$1.04/share today.

If this wasn’t enough, Regulus Therapeutics also has a Zacks Rank #5 (Strong Sell) which puts it into unfortunate company among its peers. So, given all of these factors, investors may want to consider exiting this stock now before it falls back to Earth.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>